Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability

被引:42
作者
Linton, David [1 ,2 ]
Barr, Alasdair M. [1 ,2 ]
Honer, William G. [1 ,3 ]
Procyshyn, Ric M. [1 ,3 ]
机构
[1] BC Mental Hlth & Addict Res Inst, Vancouver, BC V5Z 4H4, Canada
[2] Univ British Columbia, Biomed Res Ctr, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada
[3] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada
基金
加拿大健康研究院;
关键词
Antipsychotic agents; Central nervous system stimulants; Combination therapy; Guidelines; Attention-deficit/hyperactivity disorder; ADHD; Disruptive behavior disorders; DBD; Oppositional defiant disorder; ODD; Conduct disorder; CD; Children; Adolescents; Psychiatry; AGGRESSIVE YOUTH TRAAY; 2ND-GENERATION ANTIPSYCHOTICS; TREATMENT RECOMMENDATIONS; NATIONAL TRENDS; DOUBLE-BLIND; WEIGHT-GAIN; CHILDREN; ADOLESCENTS; RISPERIDONE; METHYLPHENIDATE;
D O I
10.1007/s11920-013-0355-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This systematic review examines treatment guidelines, efficacy/effectiveness, and tolerability regarding the use of antipsychotics concurrently with psychostimulants in treating aggression and hyperactivity in children and adolescents. Articles examining the concurrent use of antipsychotics and psychostimulants to treat comorbid attention deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs) were identified and their results were summarized and critically analyzed. Antipsychotic and stimulant combination therapy is recommended by some guidelines, but only as a third-line treatment following stimulant monotherapy and stimulants combined with behavioral interventions to treat aggression in patients with ADHD. Some studies suggest efficacy/effectiveness for an antipsychotic and stimulant combination in the treatment of aggression and hyperactivity in children and adolescents. However, the data do not clearly demonstrate superiority compared to antipsychotic or psychostimulant monotherapy. Most studies were performed over short time periods, several lacked blinding, few studies used any placebo control, and no comparisons were made with behavioral interventions. There are concerns about the tolerability of combination therapy, but data do not suggest significantly worse adverse effects for combination compared to either antipsychotic or stimulant monotherapy. Conversely, and contrary to speculation, use of a stimulant does not significantly reduce metabolic effects of antipsychotics. Combination treatment with antipsychotics and psychostimulants is used frequently, and increasingly more often. Few studies have directly examined this combination for the treatment of ADHD and DBDs. Further studies are necessary to confirm the efficacy and tolerability of the concurrent use of antipsychotics and psychostimulants in children and adolescents.
引用
收藏
页数:11
相关论文
共 46 条
[1]   Ten Years of Antipsychotic Prescribing to Children: A Canadian Population-Based Study [J].
Alessi-Severini, Silvia ;
Biscontri, Robert G. ;
Collins, David M. ;
Sareen, Jitender ;
Enns, Murray W. .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2012, 57 (01) :52-58
[2]   Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ [J].
Aman, MG ;
Binder, C ;
Turgay, A .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2004, 14 (02) :243-254
[3]   Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence [J].
Aman, MG ;
De Smedt, G ;
Derivan, A ;
Lyons, B ;
Findling, RL .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (08) :1337-1346
[4]   Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study [J].
Armenteros, Jorge L. ;
Lewis, John E. ;
Davalos, Marisabel .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2007, 46 (05) :558-565
[5]  
Barr AM, 2011, PSYCHIAT SERV, V62, P682, DOI 10.1176/ps.62.6.pss6206_0682a
[6]   A Comparison of Antipsychotic Drug-Defined Daily Doses Versus Chlorpromazine Equivalent Doses in Patients With or Without Extrapyramidal Motor Symptoms [J].
Barr, Alasdair M. ;
Honer, William G. ;
Johnson, Joy L. ;
Wu, Tony K. Y. ;
Procyshyn, Ric M. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (06) :741-743
[7]   Preclinical models of antipsychotic drug-induced metabolic side effects [J].
Boyda, Heidi N. ;
Tse, Lurdes ;
Procyshyn, Ric M. ;
Honer, William G. ;
Barr, Alasdair M. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (10) :484-496
[8]   Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents [J].
Calarge, Chadi A. ;
Acion, Laura ;
Kuperman, Samuel ;
Tansey, Michael ;
Schlechte, Janet A. .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (02) :101-109
[9]   Toward a pathophysiology of attention-deficit/hyperactivity disorder [J].
Castellanos, FX .
CLINICAL PEDIATRICS, 1997, 36 (07) :381-393
[10]   National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007 [J].
Comer, Jonathan S. ;
Olfson, Mark ;
Mojtabai, Ramin .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2010, 49 (10) :1001-1010